“Being in a clinical trial of an experimental vaccine they soon get a vaccine, potentially, otherwise they will,” he said.
If Novavax is successful, the new vaccine could add to a broader portfolio of shots in the United States by late spring. Modern and Pfizer have deals with the United States to supply 400 million doses, enough to fully immunize 200 million people by the middle of the year, and the two companies each supply an additional 100 million doses Talking to do.
Johnson & Johnson, which recently reported that its one-dose vaccine was effective in a large US trial, may receive authorization this month, but may not be able to supply significant numbers to the United States until April Can. AstraZeneca’s US trial is also underway, and that company has a deal to supply Americans with 300 million doses of its two-shot vaccine.
But any kind of hindrance can come in the progress of Novaxax. As other vaccines are more widely available, participants participating in the trial of Novavax may opt out of the trial. Even though its results in Britain were promising, the US study may yield different results. Or the company may fail to prove to regulators that it can manufacture its vaccines on a large scale. Given the possibility that three authorized vaccines may soon be available to the public in the United States, the company is under pressure to move quickly, or put competitors at risk.
Nowax, located in Gaithersburg, Md. Struggled for years A successful product to market, and in 2019 its stock was trading so low that it was dropped from Nasdaq. Then, last spring and summer, two big deals saved it from going down. In May, the Alliance for Epidemiological Preparedness Innovations awarded the company up to $ 388 million to make its Kovid vaccine available globally. In July, it was selected by the federal government’s Operation War Speed Program to develop and sell the vaccine in the United States. Later in the summer, the company Reported encouraging results In preliminary studies.
But the company struggled last fall to launch US testing from its first target of October. Novavax has put a major gamble on manufacturing, setting up plants worldwide. But making these vaccines is a granular and unpredictable process even for experienced drug makers, and Novavax had trouble moving beyond the small batches required for initial trials.
“Things happen – small things happen,” Stanley c. Erk, Novavax president and chief executive officer said. “And so little things happen, and you lose weeks.”